TY - JOUR
T1 - Human monoclonal antibodies against amyloid-beta from healthy adults
AU - Geylis, Valeria
AU - Kourilov, Vitaly
AU - Meiner, Zeev
AU - Nennesmo, Inger
AU - Bogdanovic, Nenad
AU - Steinitz, Michael
PY - 2005/5
Y1 - 2005/5
N2 - Two anti-amyloid-beta human antibody-producing cell lines were established from amyloid-beta (Aβ)-selected lymphocytes from peripheral blood of healthy adults. ELISA and Western blot analysis showed that the monoclonal antibodies bound with high affinity to the 43 amino acid-long amyloid-beta peptide. The antigen epitope of these antibodies encountered within amino acids 1-16 of the amyloid-beta peptide. The antibodies did not bind to several immunoglobulin light chain amyloids (AL) and amylin. One of the monoclonals was tested by immunohistochemistry for the binding to frozen sections of brains derived from patients with Alzheimer's disease. It specifically and intensively stained diffuse and core amyloid-beta plaques; whereas, sections from normal brains were not stained. Concomitant staining with a commercial mouse anti-amyloid-beta monoclonal antibody co-localized with that of the human antibody. Simultaneous staining with the human antibody and Congo red implied that the antibody binds primarily to an early immature form of beta-amyloid. Human monoclonal antibodies, which resemble physiologically normal non-pathogenic and possibly protective antibodies in healthy adults, might be attractive candidates for immune therapy of Alzheimer's disease.
AB - Two anti-amyloid-beta human antibody-producing cell lines were established from amyloid-beta (Aβ)-selected lymphocytes from peripheral blood of healthy adults. ELISA and Western blot analysis showed that the monoclonal antibodies bound with high affinity to the 43 amino acid-long amyloid-beta peptide. The antigen epitope of these antibodies encountered within amino acids 1-16 of the amyloid-beta peptide. The antibodies did not bind to several immunoglobulin light chain amyloids (AL) and amylin. One of the monoclonals was tested by immunohistochemistry for the binding to frozen sections of brains derived from patients with Alzheimer's disease. It specifically and intensively stained diffuse and core amyloid-beta plaques; whereas, sections from normal brains were not stained. Concomitant staining with a commercial mouse anti-amyloid-beta monoclonal antibody co-localized with that of the human antibody. Simultaneous staining with the human antibody and Congo red implied that the antibody binds primarily to an early immature form of beta-amyloid. Human monoclonal antibodies, which resemble physiologically normal non-pathogenic and possibly protective antibodies in healthy adults, might be attractive candidates for immune therapy of Alzheimer's disease.
KW - Alzheimer's disease
KW - Anti-amyloid-beta antibodies
KW - Epstein-Barr virus
KW - Human monoclonal antibodies
KW - Immunotherapy
KW - Passive immunization
UR - http://www.scopus.com/inward/record.url?scp=13644249899&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2004.06.008
DO - 10.1016/j.neurobiolaging.2004.06.008
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 15708434
AN - SCOPUS:13644249899
SN - 0197-4580
VL - 26
SP - 597
EP - 606
JO - Neurobiology of Aging
JF - Neurobiology of Aging
IS - 5
ER -